Changes in Blood Components in Patients with Ovarian Cancer


About this study

The purpose of this study is to assemble a collection of serial plasma biospecimens from women with ovarian, primary peritoneal, or fallopian tube cancer for future research projects to identify changes in levels of various plasma components that occur during the course of ovarian cancer, including changes that occur with debulking surgery, chemotherapy, disease relapse, and subsequent therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Women 18 years or older diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (hereafter referred to as OC).

Inclusion Criteria:

  1. Women with a pathologic diagnosis of OC.
  2. Able to provide informed consent.
  3. Patients receiving treatment at Mayo Clinic Rochester.

Exclusion Criteria: 

  1. Borderline tumor or non-epithelial histology (germ cell tumor, carcinosarcoma, etc.).
  2. Other malignancy within the past five years, other than non-melanoma skin cancers that have been completely resected or cervical carcinoma in situ.
  3. Already received systemic chemotherapy for OC prior to study entry.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Block, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions